Amarin Corp Plc (AMRN)

[hvypilot]

Raf, re pricing

There's a balance.

I agree with you that if the main beneficiaries of low prices are insurance
companies then they should raise prices.

But there are other considerations.
First priority is to expand the market. Raising prices before huge sales ramp would be premature.

As JL has argued, keeping prices low also deters generic competitors. Of course, Vascepa has exclusivity for a time, but if they are have a majority of the suppliers tied up because volume is so high (due to quality of efficacy and low cost) competitors are detered.

Good questions for JT, via Elizabeth. He has answered, but I think he's got other priorities right now.

And chance is better than 50-50 (imo) that an executive for big pharma is gonna make future pricing decisions anyway.